Results 31 to 40 of about 28,682 (177)

The Anti-Leukemic Potential of Curcumin in Chronic Myeloid Leukemia: A Systematic Review of In Vitro Studies. [PDF]

Food Sci Nutr
Curcumin suppresses chronic myeloid leukemia progression through multiple molecular pathways. It inhibits BCR‐ABL1, modulates miR‐21, PKCα, and PTEN, activates DR4/DR5, blocks G2/M cell cycle progression, and inhibits HDAC. These actions collectively promote apoptosis, enhance tumor suppressor expression, and reduce leukemic cell proliferation ...
Bahari H, Salim Z, Kardanpour L, Kouchaki H, Shoja F, Rahnama I, Faridzadeh A, Zahedani MR.   +7 more
europepmc   +2 more sources

Design, Synthesis, and Biological Evaluation of Novel 1,3,4-Thiadiazole Derivatives as Potential Antitumor Agents against Chronic Myelogenous Leukemia: Striking Effect of Nitrothiazole Moiety

Molecules, 2017
In an attempt to develop potent antitumor agents, new 1,3,4-thiadiazole derivatives were synthesized and evaluated for their cytotoxic effects on multiple human cancer cell lines, including the K562 chronic myelogenous leukemia cell line that expresses ...
Mehlika Dilek Altıntop, Halil Ibrahim Ciftci, Mohamed O. Radwan, Belgin Sever, Zafer Asım Kaplancıklı, Taha F. S. Ali, Ryoko Koga, Mikako Fujita, Masami Otsuka, Ahmet Özdemir   +9 more
doaj   +1 more source

A case report of bosutinib-induced interstitial granulomatous drug reaction in a patient with chronic myelogenous leukemia: a case report

SAGE Open Medical Case Reports, 2018
Bosutinib is a BCR-ABL tyrosine kinase inhibitor approved for the treatment of Philadelphia chromosome–positive chronic myelogenous leukemia. We report a case of bosutinib-induced interstitial granulomatous drug reaction in a 50-year-old Caucasian female
Alexander B Aria, Leon Chen, Auris O Huen   +2 more
doaj   +1 more source

Association of HLA Class I and Class II genes with bcr-abl transcripts in leukemia patients with t(9;22) (q34;q11)

BMC Cancer, 2004
Background Based on the site of breakpoint in t(9;22) (q34;q11), bcr-abl fusion in leukemia patients is associated with different types of transcript proteins.
Cano Pedro, Luthra Rajyalakshmi, Mundhada Shailendra   +2 more
doaj   +1 more source

Renal tuberculosis in an imatinib-treated chronic myeloid leukemia

Brazilian Journal of Nephrology, 2020
Imatinib, which inhibits tyrosine kinase activity of Bcr-Abl protein, is a standard form of treatment for chronic myeloid leukemia (CML). Through its immunomodulatory effect it affects T cell function in a number of ways.
Abhilash Chandra, Namrata Rao, Kiran Preet Malhotra   +2 more
doaj   +2 more sources

Priapism as the first manifestation in chronic myeloid leukemia: A case report and focused review of literature

Clinical Case Reports, 2021
We report the case of a patient who was initially presented with ischemic priapism to the emergency department. He was treated with adrenaline intracavernous injections and aspiration with irrigation of the corpora cavernosa and distal shunt.
Claudia Lucia Sossa Melo, Carlos Alberto Orozco Orozco, Angela Maria Peña Castellanos, Maria Alejandra Rueda Perea, Cristian Orlando Porras Bueno, Carlos Ivan Romero Diaz, Helga Natalia Rojas Rodríguez   +6 more
doaj   +1 more source

ACUTE UNDIFFERENTIATED LEUKEMIA WITH BCR-ABL TRANSLOCATION: CASE REPORT AND LITERATURE REVIEW

Hematology, Transfusion and Cell Therapy, 2021
The 2016 WHO classification defines acute undifferentiated leukemia (AUL) as a rare type of acute leukemia (AL) without defining markers for either lymphoid or myeloid lineage commitment.
AC Cortez, AD Costa, VDA Bovolenta, MM Nascimento, J Schmidt-Filho, DRA Silveira   +5 more
doaj   +1 more source

Sphingomyelin synthase 1 activity is regulated by the BCR-ABL oncogene[S]

Journal of Lipid Research, 2013
Sphingomyelin synthase (SMS) produces sphingomyelin while consuming ceramide (a negative regulator of cell proliferation) and forming diacylglycerol (DAG) (a mitogenic factor). Therefore, enhanced SMS activity could favor cell proliferation.
Tara Ann Burns, Marimuthu Subathra, Paola Signorelli, Young Choi, Xiaofeng Yang, Yong Wang, Maristella Villani, Kapil Bhalla, Daohong Zhou, Chiara Luberto   +9 more
doaj   +1 more source

Does thyroid dysfunction happen in CML patients receiving Imatinib for treatment? [PDF]

Reviews in Clinical Medicine, 2015
Chronic myelogenous leukemia is a myeloproliferative disorder presenting with anemia, elevated blood granulocytosis and the presence of immature granulocytes, basophilia, frequently thrombocytosis and spleen enlargement.
Hossein Rahimi, Zahra Mazloum Khorasani, Saeedeh Shariati   +2 more
doaj   +3 more sources

Chronic myelogenous leukemia presenting with Morel Lavallée lesion: A case report of a rare presentation

Clinical Case Reports, 2022
Chronic myelogenous leukemia is a myeloproliferative neoplasm characterized by the BCR‐ABL1 fusion gene and the development of the Philadelphia chromosome, which leads to an increase in granulocytes and bone marrow myeloid precursors in the blood, it can
Sara S. I. Mohamed, Hana Mahmoud Qasim, Ahmed Mahfouz, Maab A. Osman, Ashraf O. E. Ahmed, Safa H. Al‐Azewi, Mohamad A. Yassin, Shehab Fareed   +7 more
doaj   +1 more source